Swedish MedTech Start-up Acorai Secures €2.3M Grant from EIC

Helsingborg, Sweden-based medtech start-up Acorai announces selection for a €2.3 million grant with a follow-on investment offer of €10 million from the European Innovation Council (EIC), which will support the company’s clinical validation and regulatory submissions to enable commercialization.

Acorai is developing a first-of-its-kind non-invasive intracardiac pressure monitoring device to improve the management of heart failure following promising results in its 350-patient Swedish pilot study. Acorai received Breakthrough Device Designation from the FDA in August 2023, which allows the company to work with FDA experts to efficiently address issues that arise during premarket review and receive an expedited review prior to submission.

Acorai’s receipt of funding from the EIC clearly demonstrates the company’s potential to make a significant impact on both the health and economic fronts, not only in Europe, but globally.


en_GBEnglish (UK)